Diagnostic microRNA markers for screening sporadic human colon cancer and active ulcerative colitis in stool and tissue

Cancer Genomics and Proteomics

Volumn 6, Issue 5, 2009, Pages 281-295

  Ahmed, Farid E ^a   Jeffries, Clark D ^b   Vos, Paul W ^c   Flake, Gordon ^d   Nuovo, Gerard J ^e   Sinar, Dennis R ^f   Naziri, Wade ^g   Marcuard, Stefan P ^h  

^a Leo Jenkins Cancer Center   (United States)

^b University of North Carolina   (United States)

^c EAST CAROLINA UNIVERSITY   (United States)

^d NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^e THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^f EAST CAROLINA UNIVERSITY   (United States)

^g Southern Surgical   (United States)

^h Carolina Digestive Disease   (United States)

Author keywords

Adenocarcinoma; Colonocyte; Diagnosis; IBD; LCM; MGB; RT qPCR

Indexed keywords

BIOLOGICAL MARKER; MESSENGER RNA; MICRORNA; RNA 18S;

ARTICLE; CANCER SCREENING; CANCER STAGING; COLON CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; FECES ANALYSIS; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LASER CAPTURE MICRODISSECTION; MICRORNA GENE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA GENE; RNA ISOLATION; SENSITIVITY AND SPECIFICITY; SEQUENCE ALIGNMENT; TISSUE; ULCERATIVE COLITIS;

HOMO SAPIENS;

EID: 74949113627     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Article

References (127)

1. Ahmed FE: Colon cancer, prevalence, screening, gene expression and mutation, and risk factors and assessment. J Env Sci Health C21: 65-131, 2003.
2. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M and Boyle P: Estimates of cancer incidence and mortality in Europe in 2006. Ann Oncol 18: 581-592, 2007.
3. Jemal A, Siegel R, Ward E, Moss SM, Amar SS, Balfour TW, James PD, Mangham CA, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 57: 43-66, 2007.
4. Shibuya K, Mathers CD, Boschi-Pinto C, Lopez AD and Murray CJ: Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000. BMC Cancer 2: 37-63, 2000.
5. Ahmed FE: Gene-gene, gene-environment and multiple interactions in colorectal cancer. J Env Sci C24: 1-101, 2006.
6. National Center for Health statistics, Division of Vital Statistics, Centers for disease control, Atlanta, GA, USA (www.cdc.gov).
7. Smith RA, Cokkinides V and Brawley OW: Cancer screening in the United States, 2009. A review of current American Cancer Society Guidelines and issues in cancer screening. CA Cancer J Clin 59: 27-41, 2009.
8. Ahmed FE: Effect of diet, life style and other environmental/ chemopreventive factors on colorectal cancer development, and assessment of the risks. J Env Sci Health C22: 91-147, 2004.
9. Scholefeld JH, Moss S, Sufi F, Mangham CM and Hardcastle JD: Effect of faecal occult blood screening on mortality from colorectal cancer: results from a rondomised controlled trial. Gut 50: 840-844, 2002.
10. Fraser CG, Matthew CM, Mowat NA, Wilson JA, Carey FA and Steele RJ: Immunochemical testing of individuals positive for guaiac faecal occult blood test in a screening programme for colorectal cancer: an observational study. Lancet Oncol 7: 127-131, 2006.
11. Smith A, Young GP, Cole SR and Bampton P: Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia. Cancer 107: 2152-2159, 2006.
12. Federici A, Giorgio Rossi P, Borgia P, Bartolozzi F, Farchi S and Gausticchi G: The immunochemical faecal occult blood test leads to higher compliance than the guaiac for colorectal cancer screening programmes: a cluster randomized controlled trial. J Med Screen 12: 83-88, 2005.
13. Gonzalez EC, Roetzheirm RG, Ferrante JM and Campbell R: Predictors of proximal vs. distal colorectal cancers. Dis Colon Rectum 44: 251-258, 2001.
14. Yamai Y, Mitsushima T, Ikuma H, Wayabe H, Okamoto M, Yoshida H, Kawabe T, Wada R and Omata M: Right-sided shift of colorectal adenomas with aging. Gastrointest Endosc 63: 453-458, 2006.
15. Mandel JS: Screening for colorectal cancer. Gastroenterol Clin N Am 37: 97-115.
16. Rex D (2006) Maximizing detection of adenomas and cancers during colonoscopy. Am J Gastroenterol 101: 2866-2877, 2008.
17. Winawer S, Fletcher R, Rex D, Bond J, Burt R, Ferrucci J, Ganiats T, Levin T, Wolf S, Johnson D, Kirk L, Litin S and Simmang C: Colorectal cancer screening and surveillance: clinical guidelines and rationale - update based on new evidence. Gastroenterology 124: 544-560, 2003.
18. American Cancer Society. Screening guidelines (www.cancer.org), ACS, Atlanta, Georgia, USA.
19. O'Leary BA, Olynyk JK, Neville AM and Platell CF: Cost-effectiveness of colorectal cancer screening: comparison of a community-based flexible sigmoidoscopy with fecal occult blood testing and colonoscopy. J Gastroenterol 19: 38-47, 2004.
20. Johnson CD, Chen MH, Toledano AY, Heiken JY, Dachman AD, Kuo MD, Menias CO, Siewert B, Cheema JI, Obregon RG, Fidler JL, Zimmerman P, Horton KM, Coakley K, Iyer RB, Hara AK, Halvorsen RA Jr, Casola G, Yee J, Herman BA, Burgart LJ and Limburg PJ: Accuracy of CT colonography for detection of large adenomas and cancers. N Eng J Med 399: 1207-1217, 2008.
21. Mazzarolo S and Brady P: Small bowel capsule endoscopy: a systematic review. South Med J 100: 274-280, 2007.
22. Winawer ST, Stewart ET, Zauber AG, Bond JH, Ansel H, Wayne JD, Hall D, Hamlin JA, Schapiro M, O'Brien MJ, Sternberg SS, Gottieb LS, Fidler JL, Zimmerman P, Horton KM, Coakley K, Iyer RB, Hara AK, Halvorsen RA Jr, Casola G, Yee J, Herman BA, Burgart LJ and Limburg PJ: A comparison of colonoscopy and double-contrast barium enema for surveillance after polypectomy. National Polyp Work Group. N Engl J Med 342: 1766-1772, 2000.
23. Ahlquist DA, Skoletsky JE, Boynton KA, Harrington JJ, Mahoney DW, Pierceall WE, Thibodeau SN and Shuber AP: Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 119: 1219-1227, 2000.
24. Traverso G, Shuber A, Levin B, Johnson C, Olsson L, Schoetz DJ Jr, Hamilton SR, Boynton K, Kinzler KW and Vogelstein B: Detection of APC mutations in fecal and DNA from patients with colorectal tumors. N Engl J Med 346: 311-320, 2002.
25. Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA and Ross MA: Fecal DNA versus fecal occult blood for colorectal cancer screening in an average-risk population. New Eng J Med 351: 2704-2714, 2004.
26. Itzkowitz SH, Jandorf L, Brand R, Rabeneck L, Schroy PC III, Sontag S, Johnson D, Skoletsky J, Durkee K, Markowitz S and Shuber A: Improved fecal DNA test for colorectal cancer screening. Clin Gastroenterol Hepatol 5: 111-117, 2007.
27. Model F, Osborn N, Ahlquist D, Gruetzmann R, Molnar B, Sipos F, Galamb O, Pilarsky C, Saeger HD, Tulassay Z, Hale K, Mooney S, Lograsso J, Adorjan P, Lesche R, Dessauer A, Kleiber J, Prostmann B, Sledziews KA and Lofta-Day C: Identification and validation of colorectal neoplasia - specific methylation markers for accurate classification of disease. Mol Cancer Res 5: 153-163, 2007.
28. 6-alkylguamne DNA-alkyltransferase activity and DNA-N7-methylguanine levels in colorectal adenoma cases and matched referents. Gut 56: 318-320, 2007.
29. Huang LH, Li LH, Yang F and Wang JF: Detection of aberrant methylation in fecal DNA as a molecular screening tool for colorectal cancer and precancerous lesions. World J Gastroenterol 13: 950-954, 2007.
30. Ladabaum U and Song K: Projected national impact of colorectal cancer screening on clinical and economic outcomes and health services demand. Gastroenterology 129: 1151-1162, 2005.
31. Levin TR: Colonoscopy capacity: can we build it? Will they come? Gastroenterology 127: 1841-1844, 2004.
32. Kinzler KW and Vogelstein B: Lessons from hereditary colorectal cancer. Cell 87: 159-170, 1996.
33. East JE, Saunders BP and Jass JR: Sporadic and syndromic hyperplastic polyps and serrated adenomas of the colon: classification, molecular genetics, natural history, and clinical management. Gastroenterol Clin N Am 37: 25-46, 2008.
34. Loftus EV Jr: Clinical epidemiology of inflammatory bowel disease: incidence, prevalence and environmental influence. Gastroenterology 126: 1504-1517, 2004.
35. Ahmed FE: The role of genes and the environment in the etiology of inflammatory bowel diseases (IBD). Exp Rev Mol Diag 6: 345-363, 2006.
36. Rossler M, Rollinger W, Mantovani-Endl L, Hagamann ML, Palme S, Berndt P, Engel AM, Pfeffer M, Karl J, Bodenmüller H, Rüschoff J, Henkel T, Rohr G, Rossol S, Rösch W, Langen H, Zolg W and Tacke M: Identification of PSME3 as a novel serum marker for colorectal cancer by combining two-dimensional Polyacrylamide gel electrophoresis with a strictly mass spectrometry-based approach for data analysis. Mol Cell Proteomics 5: 2092-2101, 2006.
37. Davies RJ, Freeman A, Morris LS, Bingham S, Dilworth S, Scott I, Laskey RA, Miller R and Coleman N: Analysis of minichromosome maintenance proteins as a novel method for detection of colorectal cancer in stool. Lancet 359: 1917-1919, 2002.
38. Xing X, Lai M, Gartner W, Xu E, Huang Q, Li H and Chen G: Identification of differentially expressed protein in colorectal cancer by proteomics: down-regulation of secretagogin. Proteomics 6: 2916-2923, 2006.
39. Melle C, Bogumil R, Ernst G, Schimmel B, Bleul A and von Eggeling F: Detecion and identification of heat-shock protein 10 as a biomarker in colorectal cancer by protein profiling. Proteomics 6: 2600-2605, 2006.
40. Leman ES, Schoen RE, Megheli A, Sokoll LJ, Chan SW and Getzenberg RH: Evaluation of colon cancer-specific antigen 2 as a potential serum marker for colorectal cancer. Clin Cancer Res 14: 1349-1354, 2008.
41. Ransohoff DF, Martin C, Wiggins WS, Hitt BA, Keku TO, Galanko JA and Sandler RS: Assessment of serum proteomics to detect large colon adenomas. Cancer Epidemiol Biomarkers Prev 17: 2188-2193, 2008.
42. Chan SK, Griffith OL, Tai IT and Jones SJ: Meta-analysis of colorectal cancer gene expression profiling studies identifies consistently reported candidate biomarkers. Cancer Epidemiol Biomarkers Prev 17: 543-552, 2008.
43. Ahmed FE, James SI, Lysle DL, Dobbs LJ Jr, Johnke RM, Flake G, Stockton P, Sinar DR, Naziri W, Evans MJ, Kovacs CJ and Allison R: Improved methods for extracting RNA from exfoliated human colonocytes in stool and RT-PCR analysis. Dig Dis Sci 49: 1889-1898, 2004.
44. Ahmed FE and Vos P: Molecular markers for human colon cancer in stool and blood identified by RT-PCR. Anticancer Res 24: 4127-4134, 2004.
45. Ahmed FE, Vos P, James SI, Lysle DT, Allison RR, Rake G, Sinar DR, Naziri W, Marcuard SP and Pennington R: Transcriptomic molecular markers for screening human colon cancer in stool and tissue. Cancer Genom Proteom 4: 1-20, 2007.
46. Ahmed FE, Vos PW, James SI, Flake G, Sinar DR, Naziri W and Marcuard SP: Standardization for transcriptomic molecular markers to screen human colon cancer. Cancer Genom Proteom 4: 419-432, 2007.
47. Ahmed FE: The role of microRNA in carcinogenesis and biomarker selection: a methodological perspective. Exp Rev Mol Diag 7: 569-603, 2007.
48. Lewis BP, Bürge CB and Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15-20, 2005.
49. Ruby JG, Jan CH and Bartel D: Intronic microRNA precursors that bypass Drosha processing. Nature 448: 83-86, 2007.
50. Cummins JM and Velculescu VE: Implication of microRNA profiling for cancer diagnosis. Oncogene 15: 6220-6227, 2006.
51. Cummins JM, He Y, Leary RJ, Pagliarini R, Diaz LA Jr, Sjoblom T, Barad O, Benturch Z, Szafranska AE, Labourier E, Raymond CK, Roberts BS, Kinzler KW, Juhl H, Vogelstein B and Velculescu VE: The colorectal microRNome. Proc Natl Acad Sci USA 103: 3687-3692, 2006.
52. Calin GA, Ferracin M, Cimmino A, Dileva G, Shimiz M, Wojcik SE, Iorio MV, Visone R, Sever NI, Fabbri M, Ludiano R, Palumbo T, Pichiorri F, Roldo C, Garzon R, Sevignani C, Rassenti L, Adler H, Volinia S, Liu CG, Kipps TJ, Negrini M and Croce CM: A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Eng J Med 353: 1793-1801, 2005.
53. Eis PS, Tam W, Sun L, Chadburn A, Li Z, Gomez MF, Lund E and Dahlberg JE: Accumulation of miR-155 and BlC RNA in human B cell lymphomas. Proc Natl Acad Sci USA 102: 3627-3632, 2003.
54. Tili E, Michaille JJ, Ghandi V, Plunkett W, Sampath D and Calin GA: miRNAs and their potential for use against cancer and other diseases. Future Oncol 3: 521-537, 2007.
55. Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866, 2006.
56. Chang-Zheng C: MicroRNAs as oncogenes and tumor supressors. N Eng J Med 353: 1768-1771, 2005.
57. Calin GA, Sevignai C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M and Croce CM: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 101: 2999-3004, 2004.
58. Rosenfeld N, Aharonov R, Meiri E, Rosenwald S, Spector Y, Zepeniuk M, Benjamin H, Shabes N, Tabak S, Levy A et al: MicroRNAs identify cancer tissue origin. Nat Biotechnol 26: 462-469, 2008.
59. Griffiths-Jones S, Saini HK, van Dongen S and Enright AJ: miRBase: tools for microRNA genomics. Nucleic Acids Res 36: D154-D158, 2008.
60. Schepler T, Reinert JT, Oslenfeld MS, Christensen LL, Silahtaroglu AN, Dyrskjøt L, Wiuf C, Sørensen FJ, Kruhøffer M, Laurberg S, Kauppinen S, Ørntoft T and Andersen CL: Diagnostic and prognostic microRNAs in Stage II colon cancer. Cancer Res 68: 6416-6424, 2008.
61. Barbarotto E, Schmittgen TD and Calin GA: MicroRNAs and cancer: Profile, profile, profile. Int J Cancer 122: 969-977, 2008.
62. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, Yuen ST, Chan TS, Kwong DLW, Au GKH, Liu CG, Calin GA and Harris CC: MicroRNA expression profile associated with progression and therapeutic outcome in colon adenocarcinoma. J Am Med Assoc 299: 425-436, 2008.
63. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB and Tewari M: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105: 10513-10518, 2008.
64. Volinia S, Calin GA, ZLiu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Lorio M, Roldo C, Ferracin M, Prucitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC and Croce CM: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103: 2257-2261, 2006.
65. Bandrés E, Cubedo E, Agirre X, Malumbres R, Zárate R, Ramirez N, Abajo A, Navarro A, Moreno I, Monzó M and García- Foncillas J: Identification by real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumor tissues. Mol Cancer 5: 29, 2006.
66. Grady WM, Paekin RK, Mitchell PS, Lee JH, Kim YH, Tsuchiya KD, Washington MK, Paraskeva C, Willson JKV, Kaz AM, Kroh EM, Allen A, Fritz BR, Markowitz SD and Tewari M: Epigenetic silencing in the intronic microRNA has-miR-342 and its host gene EVL in colorectal cancer. Oncogenes 27: 3880-3888, 2008.
67. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, Li Q, Li X, Wang W, Zhang Y, Wang I, Jiang X, Xiang Y, Xu C, Zheng P, Zhang J, Li R, Zhang H, Shang X, Ning G, Wang J, Zen K, Zhang J and Zhang CY: Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18: 997-1006, 2008.
68. Jiang J, Lee EJ, Gusev Y and Schmittgen TD: Real-time expression profiling of microRNA precursors in human cancer cell lines. Nucleic Acids Res 33: 5394-5403, 2005.
69. Shi B, Stepp-Lorenzino L, Prisco M, Linsley P, deAngelis T and Baserga R: MicroRNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells. J Biol Chem 282: 32582-32590, 2007.
70. Guo C, Sah JF, Beard L, Willson JKV, Markowitz SD and Guda K: The noncoding RNA miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers. Genes Chromosomes Cancer 47: 939-946, 2008.
71. Akao Y, Nakagawa Y and Naoe T: Let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biol Pharm Bull 29: 903-906, 2006.
72. Michael MZ, O'Connor SM, van Hoist Pellekaan NG, Young GP and James RJ: Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 1: 882-891.
73. Diaz R, Silva J, Garcia JM, Lorenzo Y, Garcia V, Pena C, Rodriguez R, Munoz C, Garcia F, Bonilla F and Dominguez G (2008) Desregulated expression of miR-106a predicts survival in human colon cancer patients. Genes Chromosomes Cancer 47: 794-802, 2003.
74. Slaby O, Svoboda M, Fabian P, Serdova T, Knoflickova D, Bednarikova M, Nenatil R and Vyzala R: Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology 72: 397-402, 2007.
75. RNAi News: Rosetta Genomics aims to launch blood-based miRNA colon cancer test in 2010. RNAi News, March 10: 17, 2009.
76. Wu F, Zikusoka M, Trindade A, Dassopoulos T, Harris ML, Bayless TM, Brant SR, Chakravarti S and Kwon JH: MicroRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory particle-2-ct. Gastroenterology 135: 1626-1635, 2008.
77. Lanza G, Ferracin M, Gafa R, Veronese A, Spizzo R, Pichiorri F, Liu CG, Calin GA, Croce CM and Negrini M: mRNA/ microRNA gene expression profile in microsatellite unstable colorectal cancer. Mol Cancer 6: 54, 2007.
78. Gusev Y: Computational methods for analysis of cellular functions and pathways collectively targeted by differentially expressed microRNA. Methods 44: 61-72, 2008.
79. Gusev Y, Schmittgen TD, Lerner M, Postier R and Brackett D: Computational analysis of biological functions and pathways collectively targeted by coexpressed microRNAs in cancer. BMC Bioinformatics 8(Suppl 7): S16, 2007.
80. Deschner EE: Early proliferative changes in gastrointestinal neoplasia. Am J Gastroenterol 77: 207-211, 1982.
81. Osborn NK and Ahlquist DA: Stool screening for colorectal cancer: molecular approaches. Gastroenterology 128: 192-206, 2005.
82. Ranshoff DF: Bias as a threat to the validity of cancer molecular marker research. Nature Rev Cancer 5: 142-149, 2005.
83. Ahmed FE: Laser microdissection: application to carcinogenesis. Cancer Genom Proteom 3: 217-226, 2006.
84. Willis MS, Fuda FS and Chenault CB: Current methods of colorectal cancer screening. Med Lab Obser 34: 12-19, 2002.
85. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, Barbisin M, Xu NL, Mahuvakar VR, Andersen MR, Lao KQ, Livak KJ and Guegler KJ: Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 33: el79, 2005.
86. Lee EJ and Schmittgen TD: Comparison of RNA assay methods used to normalize cDNA for quantitative real-time PCR. Anal Biochem 357: 299-301, 2006.
87. Ahmed FE: qRT-PCR: application to carcinogenesis. Cancer Genom Proteom 2: 317-332, 2005.
88. Wegman E: Hypothetical data analysis using parallel coordinates. J Am Stat Assoc 85: 644-675, 1990
89. Tellman G: The E-method: a highly accurate technique for gene-expression analysis. Nature Methods 3: 1-2, 2006.
90. LightCycler Software®, Version 3.5, Roche Molecular Biochemicals, Mannheim, Germany, pp. 64-79, 2001.
91. Pfaffl M W: Quantification strategies in real-time PCR. In: A-Z of Quantitative PCR. Bustin SA (ed.). La Jolla, CA, USA, International University Line, pp. 89-120, 2004.
92. T method. Methods 25: 402-408, 2001.
93. Tichopad A, Dilger M, Schwarz G and Pfaffl MW: Standardised determination of real-time PCR efficiency from a single reaction setup. Nucleic Acids Res 31: 21-33, 2003.
94. Benjamini Y and Hochberger Y: Controlling false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc B 57: 289-300, 1995.
95. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP and Bürge CB: Prediction of mammalian microRNA taegets. Cell 115: 787-798, 2003.
96. Alexander RJ and Raicht RF: Purification of total RNA from human stool samples. Dig Dis Sci 43: 2652-2658, 1998.
97. Morrison TB, Weis JJ and Wittwer, CT: Quantitation of low copy transcripts by continuous SYBR Green I monitoring during amplification. BioTechniques 24: 954-959, 1998.
98. Singer M and Berg P: Determining the number of copies of a DNA sequence in a gene. In: Genes and Genomes: A Changing Perspective, pp. 396-400. Mill Valley, California, University Science Books, 1991.
99. Wong ML and Medrano JF: Real-time RT-PCR for mRNA quantitation. BioTechniques 39: 1-11, 2005.
100. Wang C, Gao D, Vaglenov A and Kaltenboeck B: One-step real-time duplex reverse transcription PCRs simultaneously quantify analyte and housekeeping gene mRNAs. BioTechniques 36: 508-519, 2004.
101. McPherson MJ and Møller SG: PCR: The Basics from Background to Bench. Berlin, Springer-Verlag, 2000.
102. Kim J, Krichevsky A, Grad Y, Hayes GD, Kosik KS, Church GM and Ruvkun G: Identification of many microRNAs that copurify with polyribosomes in mammalian neurons. Proc Natl Acad Sci USA 101: 360-365, 2004.
103. Schmittgen TD, Lee EJ, Jiang J, Sarkar A, Yang L, Elton TS and Chen C: Real-time PCR quantification of precursor and mature microRNA. Methods 44: 31-38, 2008.
104. Kaufman PB, Wu W, Kim D and Cseke LJ: Analysis of gene expression by semiquantitative PCR. In: Molecular and Cellular Methods in Biology and Medicine, pp. 245-262. CRC Press, Boca Raton, Fl, 1995.
105. de Kok JB, Roelofs RW, Giesendorf BA, Pennings JL, Waas ET, Feuth T, Swinkels DW and Span PN: Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genes. Lab Invest 85: 154-159, 2005.
106. Thellin O, Zorzi W, Lakaye B, De Borman B, Coumans B, Hensen G, Grisan T, Igout A and Heines E: Housekeeping genes as internal standards: use and limits. J Biotechnol 76: 291-296, 1999.
107. DeMuth JP, Jackson CM, Weaver DA, Crawford EL, Durzinsky DS, Durham SJ, Zaher A, Phillips ER, Khuder SA and Willey JC: The gene expression index cmyc × E2F-1/p21 is highly predictive of malignant phenotype in human bronchial epithelial cells. Am J Respir Cell Mol Biol 19: 18-29, 1998.
108. Ngan CY, Yamamoto H, Seshimo I, Ezumi K, Terayama M, Hemmi H, Takemasa I, Ikeda M, Sekimoto M and Monden M: A multivariate analysis of adhesion molecules expression in assessment of colorectal cancer. J surg Oncol 95: 652-662, 2007.
109. Hunter MP, Ismail N, Zhang X, Aguda BD, Lee EJ, Yu L, Xiao T, Schofer J, Lee MLT, Schmittgen TD, Nana-Sinkam SP, Jarjoura D and Marsh CB: Detection of microRNA expression in human peripheral blood microvesicles. PLOS One 3: e3694, 2008.
110. Simpson RJ, Lim JWE, Moritz RL and Mathivanan S: Exosomes: proteomic insights and diagnostic potential. Exp Rev Proteomics 6: 267-283, 2009.
111. Rabinowits G, Gercel-Taylor C, Day JM, Taylor DD and Kloecker GH: Exosomal microRNA: a diagnostic marker for lung cancer. Clin Lung Cancer 10: 42-46, 2009.
112. Yantiss RK, Goodarzi M, Zhou XK, Rennert H, Pirog EC, Banner BF and Chen YT: Clinical, pathologic, and molecular features of early-onset colorectal carcinoma. Am J Surg Pathol 33: 572-82, 2009.
113. Grimson A, Kyle Kai-How Farh KK-H, Johnston WK, Garrett-Engele P, Lim LP and Bartel DP: MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell 27: 91-105, 2007.
114. Huang da W, Sherman BT and Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protocol 4: 44-57, 2009.
115. Suzuki HI, Yamagata K, Sugimoto K, Iwamoto T, Kato S and Miyazono K: Modulation of microRNA processing by p53. Nature 460: 529-533, 2009.
116. Tay Y, Zhang J, Thomson AM, Lim B and Rigoutsos I: MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation. Nature 455: 1124-1128, 2008.
117. Lu M, Zhang Q, Deng M, Miao J, Guo Y, Gao W and Cui Q: An analysis of human microRNA and disease associations. PLoS one 3: e3420, 2008.
118. Rutherford SL: Between genotype and phenotype: protein chaperones and evolvability. Nat Rev Genet 4: 263-274, 2003.
119. Brodersen P and Voinnet O: Revisiting the principles of microRNA target recognition and mode of action. Nat Rev Mol Cell Biol 10: 141-148, 2009.
120. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, Jackson AL, Linsley PS, Chen C, Lowe SW, Cleary MA and Hannon GJ: A microRNA component of the p53 tumor suppressor network. Nature 447: 1130-1134, 2007.
121. Kiriakidou M, Nelson PT, Kouranov A, Fitziev P, Bouyiokos C, Mourelatos Z and Hatzigeorgiou A: A combined computational-experimental approach predicts human microRNA targets. Genes Dev 18: 1165-1178, 2004.
122. John BB, Enright AJ, Aravin A, Tuschl T, Sander C and Marks DS: Human microRNA target. PLOS Biol 2: e363, 2004.
123. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, MacMenamin P, da Piedale I, Gunsalus KC, Stoffel M and Rajewsky N: Combinational microRNA target predictions. Nature Genet 37: 495-500, 2005.
124. Pepe MS, Feng Z, Janes H, Bossuyt PM and Potter JD: Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst 100: 1432-1438, 2008.
125. Koss LG and Melamed MR (eds.): Koss' Diagnostic Cytology and Histopathologic Bases, 5th edition. Lippincott, Williams & Wilkins, 2005.
126. Petrelli NJ, Letourneau R, Weber T, Nava ME and Rodriguez-Bigas M: Accuracy of biopsy and cytology for the preoperative diagnosis of colorectal adenocarcinoma. J Surg Oncol 71: 46-49, 1999.
127. Matsushita HM, Matsumura Y, Moriya Y, Akasu T, Fujita S, Yamamoto S, Onouchi S, Saito A, Sugito M, Ito M, Kozu T, Minowa T, Momura S, Tsunoda H and Kakizoe T: A new method for isolating colonocytes from naturally evacuated feces and its clinical application to colorectal cancer diagnosis. Gastroenterology 129: 1918-1927, 2005.